Laura Huppert, MD

Articles

Best Practices in Managing Patients on Capivasertib

November 4th 2024

Panelists discuss the key advice they would offer to fellow physicians, nurse practitioners, advanced practice providers, and pharmacists involved in the care of patients on capivasertib, emphasizing best practices for patient management and communication.

Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia

November 4th 2024

Panelists discuss their approach to monitoring and managing hyperglycemia in patients receiving capivasertib and providing education about it, including when to involve endocrinology and how management strategies may differ for patients with preexisting diabetes.

Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy

October 28th 2024

Panelists discuss the strategies they employ to manage adverse events in patients starting capivasertib, including minimizing the risk of diarrhea through dietary considerations and patient education, as well as approaches for monitoring and managing rash associated with the treatment and providing education about it.

Clinical Experience with Capivasertib

October 28th 2024

Panelists discuss their clinical experiences with capivasertib, focusing on patient tolerability and the management of adverse effects associated with this targeted therapy.

Overview of the CAPItello-291 Trial

October 21st 2024

Panelists discuss the findings of the CAPItello-291 trial, which investigated capivasertib combined with fulvestrant in advanced hormone receptor–positive, HER2-negative breast cancer, leading to its approval in November 2023 and highlighting its potential as a new targeted therapy option in the second-line setting due to the prevalence of PIK3CA, AKT1, and PTEN alterations.

Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer

October 21st 2024

Panelists discuss how aberrations in the PI3K/AKT/PTEN pathway drive treatment resistance and disease progression following first-line therapy in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the critical role of repeat biomarker testing to guide ongoing treatment strategies and enhance patient outcomes.

First-Line Treatment Strategies for HR+/HER2- Advanced Breast Cancer

October 14th 2024

Panelists discuss how to approach selecting first-line treatment options for hormone receptor–positive, HER2-negative advanced breast cancer by providing an overview of standard-of-care options and highlighting the primary considerations that guide treatment selection.

Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer

October 14th 2024

Panelists discuss how biomarker testing plays a critical role in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the timing of testing, the relevance of specific genomic assays, and the significant impact on prognosis and treatment decisions.

Dr Huppert on Data Informing the Sequence of Systemic Therapy in Early-Stage TNBC

March 9th 2024

Laura A. Huppert, MD, discusses data informing the sequence of immunotherapy and chemotherapy regimens in early-stage triple-negative breast cancer.

Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer

February 23rd 2024

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.

Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer

February 16th 2024

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.

The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer

February 16th 2024

The TROPION-Breast01 trial studied the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) in previously treated HR+, HER2- breast cancer patients and showed improved progression-free survival to 7 months compared to 4.5 months with standard chemotherapy, with less high grade toxicity observed with Dato-DXd.

The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer

February 9th 2024

The EMERALD study showed improved progression-free survival with elacestrant compared to standard endocrine therapy in patients with ESR1 mutations who progressed on prior AI and CDK4/6 inhibitors, with the greatest benefit in those having longer duration of response to first-line therapy.

CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer

February 9th 2024

Laura Huppert, MD, and Yara Abdou, MD, discuss the CAPItello-291 trial which looked at the efficacy of capivasertib, a small molecule AKT inhibitor, in combination with fulvestrant for patients with estrogen receptor positive, HER2 negative advanced breast cancer who had progressed on prior endocrine therapy.

Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, review approaches to repeat hormone receptor and HER2 status testing before initiating later lines of therapy in patients with metastatic breast cancer.

The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, discuss data from the MAINTAIN trial on ribociclib in combination with endocrine therapy in patients with metastatic breast cancer.

Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer

February 2nd 2024

Laura Huppert, MD, and Yara Abdou, MD, provide an overview of the treatment landscape for HR+, HER2- advanced or metastatic breast cancer.

Dr Huppert on Sequential Treatment with T-DXd and Sacituzumab Govitecan in HER2-Low Breast Cancer

December 21st 2023

Laura A. Huppert, MD, discusses the impact of sequential treatment with fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy on outcomes in patients with HER2-low metastatic breast cancer, according to findings from a retrospective analysis.

An Overview of HR+, HER2- Metastatic Breast Cancer

December 18th 2023

Experts provides an overview of HR-positive , HER2-negative metastatic breast cancer and current treatment approaches.